Clinique de la Sauvegarde

Lyon 69009

0 studies enrolling now · 4 studies all time

What they study most

Cholangiocarcinoma, Chronic Pain, Follicular Lymphoma, Receptors, Fibroblast Growth Factor, Urothelial Cancer

Studies at this site

• Patient Retrospective Outcomes (PRO) — Recruiting now
• Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — Running, not enrolling
• A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations — Completed
• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed